Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytarabine/daunorubicin - Jazz Pharmaceuticals

Next Previous
Drug Profile

Cytarabine/daunorubicin - Jazz Pharmaceuticals

Alternative Names: CPX-351; Cytarabine/daunorubicin liposomal; Cytarabine:daunorubicin - Jazz Pharmaceuticals; Cytarabine:daunorubicin liposome injection - Jazz Pharmaceuticals; Daunorubicin/cytarabine; JZP-351; Liposomal AraC-Daunorubicin CPX-351; NS 87; VYXEOS; Vyxeos; Vyxeos Liposomal

Latest Information Update: 06 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celator Pharmaceuticals
  • Developer Cardiff University; Celator Pharmaceuticals; Children's Oncology Group; Cincinnati Childrens Hospital Medical Center; Fred Hutchinson Cancer Research Center; Jazz Pharmaceuticals plc; National Cancer Institute (USA); Nippon Shinyaku; Pfizer; Stanford University; The Leukemia & Lymphoma Society; University of California at Irvine; University of Washington; Weill Cornell Medical College
  • Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Haematological malignancies; Lymphoma

Most Recent Events

  • 07 Dec 2024 Efficacy and adverse events data from phase II trial in Acute myeloid leukaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 26 Mar 2024 Registered for Acute myeloid leukaemia in Japan (IV)
  • 14 Sep 2023 Jazz Pharmaceuticals completes a phase II trial in Precursor cell lymphoblastic leukaemia lymphoma in USA (IV, Injection) (NCT03575325)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top